Hydralyte

Execution of Variation to Facility Agreement with PURE Asset Management, Company to Seek a Sale Transaction

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) advises that today it has signed a variation to its facility agreement with boutique asset manager and existing substantial shareholder PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (PURE or PURE Asset Management) as previously announced to the market on 17 October 2022 (Original PURE Facility).


KEY HIGHLIGHTS

  • Variation provides A$1.7m in new funding, subject to the requirement of a waiver of ASX Listing Rule 10.1 in order to amend the Original PURE Facility
  • Variation includes the potential for two additional tranches valued at A$1.5m each, which can be accessed at the discretion of PURE Asset Management
  • New funding will be used in order to seek to implement a sale of the Company or the Company’s business (‘Sale Transaction’) for the benefit of stakeholders
  • Hydralyte to operate in the ordinary course of business as it progresses a Sale Transaction
Under the terms of the variation (Amended PURE Facility), Hydralyte has secured A$1.7m in new funding. The Amended PURE Facility also includes two additional tranches, valued at A$1.5m each, which can be accessed at the discretion of PURE Asset Management. The Company notes that a condition precedent to the Amended PURE Facility becoming effective (and thus access to the $1.7m of funding under the Amended PURE Facility becoming available), is the requirement of a waiver of ASX Listing Rule 10.1 in order to vary the Original PURE Facility. The Company will submit a waiver application to the ASX on or shortly after the date of this announcement in order to apply for the required waiver. The Company cautions that there is no certainty that this requirement will be met, in which case the Amended PURE Facility will not take effect (and the additional funding will not become available).

The Company intends to use the funding available under the Amended PURE Facility to progress a Sale Transaction.

While the Company advances opportunities associated with a Sale Transaction, it will continue to operate in the ordinary course of business. Hydralyte has sufficient inventory on hand to satisfy retail demand and remains actively engaged with existing and potential new stockists. The Board and management are continuing to review additional cost reductions measures, which will allow the Company to prolong its existing cash balance, which at 26 March 2024 is US$1.2m.

A detailed summary of the terms of the Amended PURE Facility and the ‘Second Warrant Deed’ entered into between the Company and PURE is provided below.

Company to seek a Sale Transaction

The Company is not expected to be cashflow positive in the near-term and requires significant additional capital to execute on its market opportunity in North America and Canada.

Market conditions are presently very challenging for emerging companies that are yet to become cash flow positive. The Company’s leveraged balance sheet adds further complexity and difficulty in raising capital.

The Board engaged New York-based Two Roads Capital in 2H2023 in order to seek to procure a strategic equity investor, change of control transaction or asset divestment for the benefit of shareholders (refer Appendix 4E of 29 February 2024). The Company is currently in progressed discussions with certain potential acquirers, however no binding or non-binding offer has been received in writing and there is no guarantee that any Sale Transaction will eventuate. The Company will update the market as and when required in accordance with the Listing Rules.

The Company has assessed and sought to execute on a range of different funding options in order to capitalise the business. It has been unable to garner sufficient support from shareholders for an equity capital raising and has been unable to procure new equity investors.

The Board is of the view that the Company is unable to access the level of capital required to get the business to breakeven or better in a short period of time, resulting in the Board’s decision to seek a Sale Transaction to maximise shareholder returns.

PURE Asset Management, which holds 11.4% of the Company’s issued shares, has agreed to vary the Original PURE Facility in order to advance the Company an additional A$1.7m (for a total of A$8.2m of senior secured debt which would be owed to PURE), in order to fund the business while it seeks a Sale Transaction for the benefit of all stakeholders. The Amended PURE Facility requires a waiver of ASX Listing Rule 10.1 in order to take effect. If the Amended PURE Facility does not take effect then the Original PURE Facility will not be amended and the additional funding will not be available.

The Amended PURE Facility also includes two new additional tranches, valued at A$1.5m each, which can be accessed at the discretion of PURE Asset Management. The Amended PURE Facility also provides for a ‘Second Loan’ of $5.5m, which can be accessed at the discretion of PURE Asset Management until 31 December 2024. The Second Loan was provided for in the Original PURE Facility and the terms of the Second Loan were amended as announced on 3 August 2023.

Assuming drawdown of the $1.7m, this amount, plus net cash at bank is expected to be exhausted in July 2024.

In the event that the Company is unable to procure a Sale Transaction by July 2024, additional debt or equity capital would be required in order for the Company to continue operations as a going concern. While the Amended PURE Facility contemplates two additional tranches of a total of A$3.0m of debt available (in addition to the ‘Second Loan’ of $5.5m), the availability of those additional tranches (and the Second Loan) is at PURE’s discretion. If additional capital was required, there is no guarantee that the Company would be able to raise it.

The Company has chosen to obtain the debt from PURE (a ‘Listing Rule 10.1 party’ by virtue of its 11.4% shareholding in the Company) via the Amended PURE Facility because it is unable to raise any meaningful level of equity capital from existing shareholders or new investors in the time period required. After assessing a range of options, the Board considers that the debt being provided by PURE is the only funding available within the current time requirements.

Given the above comments including the lack of success with alternative funding, the Board considers that the terms of the Amended PURE Facility are fair and reasonable for shareholders.


Click here for the full ASX Release

This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

HPC:AU
Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less
Amplia Therapeutics

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less
  InhaleRX

InhaleRx Secures $38,500,000 Funding to Fully Fund Clinical Development Plans

InhaleRx Ltd (ASX: IRX) (‘InhaleRx’ ‘IRX’ or ‘the Company’), an Australian healthcare company developing unique drug-device products to address unmet medical needs in pain management and mental health sectors, is pleased to announce that it has entered into a significant funding agreement with Clendon Biotech Capital Pty Ltd (‘Clendon Biotech Capital’). This strategic partnership will provide the funding to cover all direct costs associated with the Phase 1 & 2 clinical development of the Company's key projects - IRX-211 and IRX-616a.

Keep reading...Show less
  TrivarX

Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to announce positive top-line results from the Company’s recently completed Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study utilising its proprietary AI-backed algorithm, MEB-001. MEB-001 uses EEG and ECG signals recorded during sleep to identify current Major Depressive Episode (cMDE).

Keep reading...Show less
Tryptamine Therapeutics Limited

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company is pleased to advise it has received highly encouraging, positive results from its recently completed Phase 2a clinical trial conducted in collaboration with the University of Michigan (‘UOM’) (refer ASX announcement: 10 July 2024). The results are both significant and clinically meaningful, and were presented by UOM researchers at the International Association for the Study of Pain (‘IASP’) 2024 World Congress in the Netherlands on 9 August 2024.

Keep reading...Show less
Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×